Bacillus calmette-Guérin plus intravesical interferon alpha-2b in patients with superficial bladder cancer
- 31 December 1996
- Vol. 48 (6) , 957-962
- https://doi.org/10.1016/s0090-4295(96)00375-5
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Antiproliferative effects of bacillus Calmette-Guérin and interferon α2b on human bladder cancer cells in vitroCancer Immunology, Immunotherapy, 1995
- Original Articles: Bladder Cancer: A Randomized Study of Intravesical Mitomycin C, Bacillus Calmette-Guerin Tice and Bacillus Calmette-Guerin RIVM Treatment in pTa-pT1 Papillary Carcinoma and Carcinoma in Situ of the BladderJournal of Urology, 1995
- Cancer statistics, 1995CA: A Cancer Journal for Clinicians, 1995
- Improving the Safety of BCG Immunotherapy by Dose ReductionEuropean Urology, 1995
- High-dose versus low-dose intravesical interferon-α2b in the treatment of carcinoma in situAnti-Cancer Drugs, 1992
- Bacillus Calmette-Guerin Therapy for Superficial Bladder Cancer: A 10-Year FollowupJournal of Urology, 1992
- A Low Dose Bacillus Calmette-Guerin Regimen in Superficial Bladder Cancer Therapy: Is it Effective?Journal of Urology, 1991
- A Randomized Controlled Study of Intravesical α−2b-Interferon in Carcinoma in Situ of the BladderJournal of Urology, 1990
- Alpha-interferon in superficial bladder cancer: a Northern California Oncology Group Study.Journal of Clinical Oncology, 1988
- Intracavitary Bacillus Calmette-guerin in the Treatment of Superficial Bladder TumorsJournal of Urology, 1976